Table 5.
Multivariate † model odds ratios and 95% confidence intervals for early age-related macular degeneration (AMD), assessed from 2001–2004, among participants (<75 years) reporting high compared to low levels of sunlight exposure and consuming high compared to low intake of vitamin D from foods and supplements, assessed in1993–1998: Carotenoids in Age-Related Eye Disease Study CAREDS (n=968).
| Time spent in sunlight (hours/day) | < 1 hours | 1 to 3 hours | >3 hours | P for trend* | ||
| # with AMD/# in sunlight category | 49/384 | 75/483 | 15/101 | |||
| Multivariate model ‡ | 1.0 | 1.15 (0.78–1.72) | 1.15 (0.59–2.15) | 0.46 | ||
| Total vitamin D intake from foods and supplements combined | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | P for trend* |
| Quintiles, μg/day (median (range)) | 2.8 (0.4–4.5) | 6.5 (>4.5–9.5) | 12.2 (>9.5–14) | 15.8 (>14–18) | 21.4 (>18–61) | |
| # with AMD/# in quintile | 36/211 | 24/200 | 37/196 | 28/177 | 14/184 | |
| Multivariate model | 1.00 | 0.67 (0.38–1.18) | 1.09 (0.65–1.84) | 0.90 (0.51–1.56) | 0.41 (0.20–0.78) | 0.15 |
| Vitamin D intake from supplements, μg/day | None | >0 to <10 μg | 10 μg | >10 μg | P for trend* | |
| # with AMD/# in supplement use category | 64/407 | 17/120 | 44/301 | 14/140 | ||
| Multivariate model | 1.00 | 0.85 (0.46–1.50) | 0.89 (0.58–1.36) | 0.59 (0.30–1.09) | 0.60 | |
| Vitamin D intake from foods | Quintile 1 | Quintile 2 | Quintile 3 | Quintile 4 | Quintile 5 | P for trend* |
| Quintiles, μg/day (median (range)) | 2.0 (0.4–2.7) | 3.5 (>2.7–4.2) | 5.0 (>4.2–5.8) | 7.0 (>5.8–8.6) | 10.6 (>8.6–30.4) | |
| # AMD/# in quintile | 30/206 | 34/198 | 35/201 | 21/189 | 19/174 | |
| Multivariate model | 1.00 | 1.20 (0.69–2.08) | 1.24 (0.72–2.16) | 0.75 (0.41–1.37) | 0.74 (0.39–1.38) | 0.04 |
A P-value was obtained for the linear trend by replacing the categorical predictor with the continuous variable.
Worse eye, adjusted for age at photography, and risk factors for age-related macular degeneration (smoking pack years, iris pigmentation, family history of AMD, cardiovascular disease, diabetes, and hormone use status).